MedTrace Logo

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2026-03-24

No results posted yet for this study

Summary

Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.

Conditions

Interventions

DRUG

Etavopivat A

Participants will receive an oral dose of Etavopivat A.

DRUG

Etavopivat B

Participants will receive an oral dose of Etavopivat B.

DRUG

Etavopivat C

Participants will receive an oral dose of Etavopivat C.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2030-12-30
Completion
2030-12-30
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Egypt
  • France
  • Germany
  • Ghana
  • Greece
  • India
  • Italy
  • Kenya
  • Lebanon
  • Nigeria
  • Oman
  • Saudi Arabia
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06609226 on ClinicalTrials.gov